Angiogenesis in endocrine tumors.
暂无分享,去创建一个
Adrian L Harris | A. Harris | S. Melmed | J. Wass | Shlomo Melmed | H. Turner | Helen E Turner | John A H Wass
[1] R. Muschel,et al. Inhibition of matrix metalloproteinase 9 expression by a ribozyme blocks metastasis in a rat sarcoma model system. , 1996, Cancer research.
[2] J. Folkman,et al. Tumor angiogenesis: iris neovascularization at a distance from experimental intraocular tumors. , 1973, Journal of the National Cancer Institute.
[3] P. Comoglio,et al. Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1997 by The Endocrine Society Negative/Low Expression of the Met/Hepatocyte Growth Factor Receptor Identifies Papillary Thyroid , 2022 .
[4] S. Melmed,et al. Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis , 1999, Nature Medicine.
[5] P. Colville-Nash,et al. Angiogenesis and rheumatoid arthritis: pathogenic and therapeutic implications. , 1992, Annals of the rheumatic diseases.
[6] M. Dewhirst,et al. Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor. , 1998, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[7] G. Popa,et al. THE VASCULAR LINK BETWEEN THE PITUITARY AND THE HYPOTHALAMUS. , 1930 .
[8] G. Chiesa,et al. Liposome-delivered angiostatin strongly inhibits tumor growth and metastatization in a transgenic model of spontaneous breast cancer. , 2000, Cancer research.
[9] T. Nakajima,et al. c‐Met expression of thyroid tissue with special reference to papillary carcinoma , 1998, Pathology international.
[10] J. Folkman. Editorial: Is Tissue Mass Regulated by Vascular Endothelial Cells? Prostate as the First Evidence. , 1998, Endocrinology.
[11] A. Buckley,et al. Proteolysis of Human Prolactin: Resistance to Cathepsin D and Formation of a Nonangiostatic, C-Terminal 16K Fragment by Thrombin1. , 1999, Endocrinology.
[12] M. Puzianowska-Kuźnicka,et al. Differential regulation of three thyroid hormone‐responsive matrix metalloproteinase genes implicates distinct functions during frog embryogenesis , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[13] J. Martial,et al. 16K human prolactin inhibits vascular endothelial growth factor-induced activation of Ras in capillary endothelial cells. , 1999, Molecular endocrinology.
[14] C. Larsson,et al. Differential loss of heterozygosity in familial, sporadic, and uremic hyperparathyroidism , 1997, Human Genetics.
[15] D. Hill,et al. Changes in the immunohistochemical localisation of fibroblast growth factor-2, transforming growth factor-beta 1 and thrombospondin-1 are associated with early angiogenic events in the hyperplastic rat thyroid. , 1996, The Journal of endocrinology.
[16] Machein,et al. Differential downregulation of vascular endothelial growth factor by dexamethasone in normoxic and hypoxic rat glioma cells , 1999, Neuropathology and applied neurobiology.
[17] P. Comoglio,et al. Expression of Met protein and urokinase‐type plasminogen activator receptor (uPA‐R) in papillary carcinoma of the thyroid , 1998, The Journal of pathology.
[18] J. Schechter,et al. Morphological evidence for the presence of arteries in human prolactinomas. , 1988, The Journal of clinical endocrinology and metabolism.
[19] Lars Holmgren,et al. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma , 1994, Cell.
[20] J. Martial,et al. Activation of mitogen-activated protein kinases by vascular endothelial growth factor and basic fibroblast growth factor in capillary endothelial cells is inhibited by the antiangiogenic factor 16-kDa N-terminal fragment of prolactin. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[21] Bing Li,et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo , 1993, Nature.
[22] C. Martínez-A,et al. The Matrix Metalloproteinase-9 Regulates the Insulin-like Growth Factor-triggered Autocrine Response in DU-145 Carcinoma Cells* , 1999, The Journal of Biological Chemistry.
[23] K. Matsumoto,et al. Identification and characterization of high molecular weight forms of basic fibroblast growth factor in human pituitary adenomas. , 1992, The Journal of clinical endocrinology and metabolism.
[24] O. Melnyk,et al. Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model. , 1999, The Journal of urology.
[25] T. Kawamoto,et al. Effects of parathyroid hormone (PTH) and PTH-related peptide on expressions of matrix metalloproteinase-2, -3, and -9 in growth plate chondrocyte cultures. , 1998, Endocrinology.
[26] P. Porter,et al. Thrombospondin-1, an inhibitor of angiogenesis, is regulated by progesterone in the human endometrium. , 1996, The Journal of clinical investigation.
[27] Y. Sinha,et al. Cleaved prolactin: evidence for its occurrence in human pituitary gland and plasma. , 1985, The Journal of clinical endocrinology and metabolism.
[28] J. Franklyn,et al. Expression of fibroblast growth factors in thyroid cancer. , 1995, The Journal of clinical endocrinology and metabolism.
[29] H. Augustin. Angiogenesis in the female reproductive system. , 2005, EXS.
[30] E Medico,et al. Met overexpression confers HGF‐dependent invasive phenotype to human thyroid carcinoma cells in vitro , 1999, Journal of cellular physiology.
[31] J. Wass,et al. Pituitary, adrenal and thyroid incidentalomas , 1998 .
[32] J. Donckier,et al. Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. , 1997, The Journal of clinical endocrinology and metabolism.
[33] A. Logan,et al. Basic fibroblast growth factor affects DNA synthesis and cell function and activates multiple signalling pathways in rat thyroid FRTL-5 and pituitary GH3 cells. , 1990, The Journal of endocrinology.
[34] G. Conway,et al. Serum vascular endothelial growth factor concentrations in postmenopausal women: the effect of hormone replacement therapy. , 2000, Fertility and sterility.
[35] P. Maher,et al. Inhibition of Cell Migration and Angiogenesis by the Amino-terminal Fragment of 24kD Basic Fibroblast Growth Factor* , 2002, The Journal of Biological Chemistry.
[36] J. Folkman,et al. Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. , 1991, The New England journal of medicine.
[37] J. Arbiser,et al. Corticotropin-releasing hormone stimulates angiogenesis and epithelial tumor growth in the skin. , 1999, The Journal of investigative dermatology.
[38] D. Basile,et al. Basic fibroblast growth factor may mediate proliferation in the compensatory adrenal growth response. , 1993, The American journal of physiology.
[39] M. Welsh,et al. Effects of vascular endothelial growth factor on pancreatic duct cell replication and the insulin production of fetal islet-like cell clusters in vitro , 1997, Molecular and Cellular Endocrinology.
[40] B. Shilo,et al. Insulin induces transcription of target genes through the hypoxia‐inducible factor HIF‐1α/ARNT , 1998, The EMBO journal.
[41] P. Marc,et al. Human growth hormone stimulates proteinase activities of rabbit bone cells via IGF-I. , 2000, Biochemical and biophysical research communications.
[42] D. Sarkar,et al. Over expression of vascular endothelial growth factor and its receptor during the development of estrogen-induced rat pituitary tumors may mediate estrogen-initiated tumor angiogenesis. , 1997, Carcinogenesis.
[43] H. Fraser,et al. Inhibition of early luteal angiogenesis by gonadotropin-releasing hormone antagonist treatment in the primate. , 2000, The Journal of clinical endocrinology and metabolism.
[44] J. Slodkowska,et al. Lung carcinoids. Tumor angiogenesis in relation to clinicopathologic characteristics. , 1999, Analytical and quantitative cytology and histology.
[45] A. Harris. von Hippel-Lindau syndrome: target for anti-vascular endothelial growth factor (VEGF) receptor therapy. , 2000, The oncologist.
[46] A. Harris,et al. The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2000 by The Endocrine Society Role of Matrix Metalloproteinase 9 in Pituitary Tumor Behavior , 2000 .
[47] K. Alitalo,et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[48] G. Viglietto,et al. Modulation of in vivo growth of thyroid tumor-derived cell lines by sense and antisense vascular endothelial growth factor gene , 1999, Oncogene.
[49] G. Giannattasio,et al. Microvasculature of human micro- and macroprolactinomas. A morphological study. , 1986, Neuroendocrinology.
[50] S. Brem,et al. Angiogenesis as a marker of preneoplastic lesions of the human breast , 1978, Cancer.
[51] K. Plate,et al. Vascular endothelial growth factor , 1997, Journal of Neuro-Oncology.
[52] E. Woltering,et al. Inhibition of angiogenesis by somatostatin and somatostatin-like compounds is structurally dependent. , 1993, The Journal of surgical research.
[53] J. Stanfield,et al. The blood supply of the human pituitary gland. , 1960, Journal of anatomy.
[54] M. Bar,et al. Sporadic phaeochromocytomas are rarely associated with germline mutations in the von Hippel‐Lindau and RET genes , 1997, Clinical endocrinology.
[55] D. King,et al. Mass spectrometric analysis of the fragments produced by cleavage and reduction of rat prolactin: evidence that the cleaving enzyme is cathepsin D. , 1993, Endocrinology.
[56] L. Ericson,et al. Blood capillary enlargement during the development of thyroid hyperplasia in the rat. , 1978, Endocrinology.
[57] D. Edwards,et al. THE MATRIX METALLOPROTEINASES AND THEIR INHIBITORS , 2005 .
[58] M. Hoshino,et al. Inhaled corticosteroids decrease subepithelial collagen deposition by modulation of the balance between matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 expression in asthma. , 1999, The Journal of allergy and clinical immunology.
[59] A. Ullrich,et al. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant , 1994, Nature.
[60] J. Amano,et al. Expression of fibroblast growth factor-2 and fibroblast growth factor receptor-1 in thyroid diseases: difference between neoplasms and hyperplastic lesions. , 1998, Endocrine journal.
[61] M. Ivan,et al. Activated ras and ret oncogenes induce over-expression of c-met (hepatocyte growth factor receptor) in human thyroid epithelial cells , 1997, Oncogene.
[62] L. Bresler*,et al. Vascular endothelial growth factor gene and protein: strong expression in thyroiditis and thyroid carcinoma. , 1999, The Journal of endocrinology.
[63] A. Kulig,et al. Inhibitory effects of fumagillin and its analogue TNP-470 on the function, morphology and angiogenesis of an oestrogen-induced prolactinoma in Fischer 344 rats. , 1996, The Journal of endocrinology.
[64] M. McCarthy,et al. Localisation of a gene causing endocrine neoplasia to a 4 cM region on chromosome 1p35-p36. , 1997, Journal of medical genetics.
[65] Erwin G. Van Meir,et al. Thrombospondins and tumor angiogenesis. , 2001, Trends in molecular medicine.
[66] W. Fantl,et al. Signalling by receptor tyrosine kinases. , 1993, Annual review of biochemistry.
[67] S. Leung,et al. Vascular endothelial growth factor is up‐regulated in the early pre‐malignant stage of colorectal tumour progression , 1999, International journal of cancer.
[68] B. Bussolati,et al. Angiopoietin-1 and angiopoietin-2 activate trophoblast Tie-2 to promote growth and migration during placental development. , 2000, The American journal of pathology.
[69] D. Hill,et al. Presence and possible role of vascular endothelial growth factor in thyroid cell growth and function. , 1998, The Journal of endocrinology.
[70] R. Warren,et al. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. , 1995, The Journal of clinical investigation.
[71] Stanfield Jp. The blood supply of the human pituitary gland. , 1960 .
[72] G. Viglietto,et al. Upregulation of the angiogenic factors PlGF, VEGF and their receptors (Flt-1, Flk-1/KDR) by TSH in cultured thyrocytes and in the thyroid gland of thiouracil-fed rats suggest a TSH-dependent paracrine mechanism for goiter hypervascularization , 1997, Oncogene.
[73] Thomas Hawighorst,et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis , 2001, Nature Medicine.
[74] U. Pagotto,et al. Pituitary adenylate cyclase-activating polypeptide, interleukin-6 and glucocorticoids regulate the release of vascular endothelial growth factor in pituitary folliculostellate cells. , 1999, The Journal of endocrinology.
[75] K. Seibert,et al. COX‐2 Inhibitors: A New Class of Antiangiogenic Agents , 1999, Annals of the New York Academy of Sciences.
[76] N. Iwahori,et al. Parathyroid hormone-related peptide is a potent tumor angiogenic factor. , 2000, Endocrinology.
[77] T. Dwight,et al. Loss of heterozygosity in sporadic parathyroid tumours: involvement of chromosome 1 and the MEN1 gene locus in 11q13. , 2000, Clinical endocrinology.
[78] S. Gruber,et al. Direct evidence linking expression of matrix metalloproteinase 9 (92-kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[79] E. Van Obberghen,et al. Insulin and Insulin-like Growth Factor-I Induce Vascular Endothelial Growth Factor mRNA Expression via Different Signaling Pathways* , 2000, The Journal of Biological Chemistry.
[80] L. Aiello,et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[81] C. Wykoff,et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis , 1999, Nature.
[82] Q. Duh,et al. Thyroid-stimulating hormone promotes the secretion of vascular endothelial growth factor in thyroid cancer cell lines. , 1996, Surgery.
[83] E. Manseau,et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. , 1993, Cancer research.
[84] G. Semenza,et al. Structural and functional analysis of hypoxia-inducible factor 1. , 1997, Kidney international.
[85] J. Smit,et al. Degradation of extracellular matrix by metastatic follicular thyroid carcinoma cell lines: role of the plasmin activation system. , 1999, Thyroid : official journal of the American Thyroid Association.
[86] E. Scanziani,et al. Antiangiogenic and antitumor activity of IDN 5390, a new taxane derivative. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[87] G. Maira,et al. Immunohistochemical detection of folliculo-stellate cells in human pituitary adenomas , 1984, Virchows Archiv. B, Cell pathology including molecular pathology.
[88] M. Witt,et al. Galactose and fucose binding sites in anterior pituitary cells of the rat. Detection by means of biotinylated lectins. , 1987, Folia histochemica et cytobiologica.
[89] R. Mitchell,et al. Pituitary follicular cells produce basic fibroblast growth factor. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[90] R. Morris,et al. Vascular endothelial growth factor in the rat pituitary: differential distribution and regulation by estrogen. , 2000, The Journal of endocrinology.
[91] M. Neeman,et al. The antiangiogenic agent linomide inhibits the growth rate of von Hippel-Lindau paraganglioma xenografts to mice. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[92] Georg Breier,et al. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo , 1992, Nature.
[93] J. Schechter,et al. Estrogen-induced tumors: changes in the vasculature in two strains of rat. , 1987, The American journal of anatomy.
[94] L. Ellis,et al. Regulation of vascular endothelial growth factor expression in human colon cancer by insulin-like growth factor-I. , 1998, Cancer research.
[95] T. Saclarides,et al. Tumor angiogenesis in pheochromocytomas and paragangliomas. , 1996, Surgery.
[96] Y. Sinha,et al. A cleaved form of prolactin in the mouse pituitary gland: identification and comparison of in vitro synthesis and release in strains with high and low incidences of mammary tumors. , 1984, Endocrinology.
[97] J. Pickard,et al. Hyperprolactinemia, intrasellar pituitary tissue pressure, and the pituitary stalk compression syndrome. , 1987, Journal of neurosurgery.
[98] M. Kirschner,et al. Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. , 1999, Science.
[99] L. Portugal,et al. Well‐differentiated thyroid carcinomas: p53 mutation status and microvessel density , 1998, Head & neck.
[100] R. Klausner,et al. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[101] L. Liotta,et al. Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family. , 1989, The Journal of biological chemistry.
[102] Saxe Aw. Angiogenesis of human parathyroid tissue. , 1984 .
[103] R. Weyant,et al. Prognostic markers in pheochromocytoma. , 1998, Human pathology.
[104] B. C. Patterson,et al. Angiostatin-converting Enzyme Activities of Human Matrilysin (MMP-7) and Gelatinase B/Type IV Collagenase (MMP-9)* , 1997, The Journal of Biological Chemistry.
[105] B. Coulombe,et al. Decreased expression of tissue inhibitor of metalloproteinases in metastatic tumor cells leading to increased levels of collagenase activity. , 1991, Cancer research.
[106] Reduced retinal vascularization in children with growth hormone deficiency. , 1999, The Journal of clinical endocrinology and metabolism.
[107] M. Pawlikowski,et al. Immunocytochemical investigations on the vascularization of pituitary adenomas , 1997, Endocrine pathology.
[108] P. Rao,et al. Expression of Tie2/Tek in breast tumour vasculature provides a new marker for evaluation of tumour angiogenesis. , 1998, British Journal of Cancer.
[109] E. Manseau,et al. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. , 1993, The American journal of pathology.
[110] Q. Duh,et al. Phenylacetate inhibits growth and vascular endothelial growth factor secretion in human thyroid carcinoma cells and modulates their differentiated function. , 1999, The Journal of clinical endocrinology and metabolism.
[111] R K Jain,et al. Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[112] C. Jackson,et al. Human microvascular endothelial cells differ from macrovascular endothelial cells in their expression of matrix metalloproteinases. , 1997, The international journal of biochemistry & cell biology.
[113] A. Douglas-Jones,et al. Epidermal Growth Factor Receptor Status in Hyperparathyroidism: Immunocytochemical and In Situ Hybridization Study , 1996, World Journal of Surgery.
[114] L. Akslen,et al. Increased angiogenesis in papillary thyroid carcinoma but lack of prognostic importance. , 2000, Human pathology.
[115] C. Patterson,et al. Induction of Vascular Endothelial Growth Factor Gene Expression by Interleukin-1 in Rat Aortic Smooth Muscle Cells (*) , 1995, The Journal of Biological Chemistry.
[116] S. Mori,et al. Colocalization of vascular endothelial growth factor (vascular permeability factor) and insulin in pancreatic islet cells. , 1995, The Journal of clinical endocrinology and metabolism.
[117] M. Neeman,et al. Loss of ovarian function promotes angiogenesis in human ovarian carcinoma. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[118] P. Opolon,et al. Combined effects of radiotherapy and angiostatin gene therapy in glioma tumor model. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[119] M. Takigawa,et al. Induction of angiogenesis in chick yolk-sac membrane by polyamines and its inhibition by tissue inhibitors of metalloproteinases (TIMP and TIMP-2). , 1990, Biochemical and biophysical research communications.
[120] M. Shibuya,et al. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[121] M. Toi,et al. Tumor angiogenesis in breast cancer: Its importance as a prognostic indicator and the association with vascular endothelial growth factor expression , 2004, Breast Cancer Research and Treatment.
[122] M. Iitaka,et al. Increased serum vascular endothelial growth factor levels and intrathyroidal vascular area in patients with Graves' disease and Hashimoto's thyroiditis. , 1998, The Journal of clinical endocrinology and metabolism.
[123] D. Talbot,et al. Experimental and clinical studies on the use of matrix metalloproteinase inhibitors for the treatment of cancer. , 1996, European journal of cancer.
[124] R. Weiner,et al. Direct arterial vascularization of estrogen-induced prolactin-secreting anterior pituitary tumors. , 1984, Proceedings of the National Academy of Sciences of the United States of America.
[125] C. Clapp,et al. A 14-kilodalton prolactin-like fragment is secreted by the hypothalamo-neurohypophyseal system of the rat. , 1995, Endocrinology.
[126] F. Basolo,et al. Inhibition of experimental angiogenesis by the somatostatin analogue octreotide acetate (SMS 201-995). , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[127] W. Scherbaum,et al. Human thyroid carcinoma cell lines and normal thyrocytes: expression and regulation of matrix metalloproteinase-1 and tissue matrix metalloproteinase inhibitor-1 messenger-RNA and protein. , 1997, Thyroid : official journal of the American Thyroid Association.
[128] A. Harris,et al. Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer , 1992, The Lancet.
[129] Anthony J. Guidi,et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. , 1995, Human pathology.
[130] H. Augustin,et al. Analysis of blood vessel maturation processes during cyclic ovarian angiogenesis. , 1998, Laboratory investigation; a journal of technical methods and pathology.
[131] J. Folkman,et al. Angiostatin induces and sustains dormancy of human primary tumors in mice , 1996, Nature Medicine.
[132] W. Kaelin,et al. Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. , 1999, Science.
[133] H. Drexhage,et al. Morphological, immunohistochemical and functional homologies between pituitary folliculo-stellate cells and lymphoid dendritic cells. , 1991, Acta Endocrinologica.
[134] A. Genazzani,et al. Correlation between the amount of follicle-stimulating hormone administered and plasma and follicular fluid vascular endothelial growth factor concentrations in women undergoing in vitro fertilization. , 1998, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.
[135] K. Kurisu,et al. Inhibitory effect of TNP-470, a new anti-angiogenic agent, on the estrogen induced rat pituitary tumors. , 1994, Anticancer research.
[136] C. Patterson,et al. Enhanced expression of vascular endothelial growth factor in human SaOS-2 osteoblast-like cells and murine osteoblasts induced by insulin-like growth factor I. , 1996, Endocrinology.
[137] S. Groshen,et al. Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. , 1995, Journal of the National Cancer Institute.
[138] M. Bednarski,et al. Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. , 1998, Nature medicine.
[139] K. Smith-McCune,et al. Demonstration and characterization of the angiogenic properties of cervical dysplasia. , 1994, Cancer research.
[140] A. Harris,et al. Proliferation, bcl-2 expression and angiogenesis in pituitary adenomas: relationship to tumour behaviour , 2000, British Journal of Cancer.
[141] K. Arita,et al. Type IV collagenase activity and cavernous sinus invasion in human pituitary adenomas , 2005, Acta Neurochirurgica.
[142] N. Ferrara,et al. The biology of vascular endothelial growth factor. , 1997, Endocrine reviews.
[143] D. Mooney,et al. Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. , 1999, The American journal of pathology.
[144] K. Alitalo,et al. Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. , 1994, The Journal of biological chemistry.
[145] U. Renner,et al. High levels of matrix metalloproteinases regulate proliferation and hormone secretion in pituitary cells. , 2000, The Journal of clinical endocrinology and metabolism.
[146] M. Brandi,et al. Proliferation of endothelial component of parathyroid gland in multiple endocrine neoplasia type 1. Potential relationship with a mitogenic factor. , 1993, The American journal of pathology.
[147] C. Heldin,et al. Expression of transforming growth factors beta 1, beta 2, beta 3 in neuroendocrine tumors of the digestive system. , 1994, Anticancer research.
[148] J. Folkman. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. , 1995, The New England journal of medicine.
[149] J. Winer,et al. Pituitary follicular cells secrete an inhibitor of aortic endothelial cell growth: identification as leukemia inhibitory factor. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[150] D. Marmé,et al. Expression of the vascular endothelial growth factor gene is inhibited by p73 , 2000, Oncogene.
[151] P. Sears,et al. Biological and immunological characterization of cleaved and 16K forms of rat prolactin. , 1988, Endocrinology.
[152] J. Schechter,et al. Activation of anterior pituitary folliculo-stellate cells in the formation of estrogen-induced prolactin-secreting tumors. , 1988, Neuroendocrinology.
[153] A. Harris,et al. Angiogenesis in pituitary adenomas and the normal pituitary gland. , 2000, The Journal of clinical endocrinology and metabolism.
[154] H M Jensen,et al. Angiogenesis induced by "normal" human breast tissue: a probable marker for precancer. , 1982, Science.
[155] Meijia Yang,et al. Angioarrestin: an antiangiogenic protein with tumor-inhibiting properties. , 2002, Cancer research.
[156] Claudio Eccher,et al. Microvessel density quantification in breast carcinomas. Assessment by light microscopy vs. a computer-aided image analysis system , 1995 .
[157] R. Weiner,et al. Formation of a direct arterial blood supply to the anterior pituitary gland following complete or partial interruption of the hypophyseal portal vessels. , 1984, Neuroendocrinology.
[158] H. Greene. HETEROLOGOUS TRANSPLANTATION OF MAMMALIAN TUMORS I. THE TRANSFER OF RABBIT TUMORS TO ALIEN SPECIES , 1941 .
[159] J. Martial,et al. Opposing actions of intact and N-terminal fragments of the human prolactin/growth hormone family members on angiogenesis: an efficient mechanism for the regulation of angiogenesis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[160] D. Hanahan,et al. Induction of angiogenesis during the transition from hyperplasia to neoplasia , 1989, Nature.
[161] R. Xavier,et al. Tumor Induction of VEGF Promoter Activity in Stromal Cells , 1998, Cell.
[162] P. Dandona,et al. Stable over-expression of estrogen receptor-α in ECV304 cells inhibits proliferation and levels of secreted endothelin-1 and vascular endothelial growth factor , 1999, Molecular and Cellular Endocrinology.
[163] R. D'Amato,et al. Regulation of Vascular Endothelial Growth Factor Expression by Insulin-Like Growth Factor I , 1997, Diabetes.
[164] J. Foekens,et al. Regulation of the urokinase-type plasminogen activator system by the von Hippel-Lindau tumor suppressor gene. , 1999, Cancer research.
[165] D. Hanahan,et al. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. , 1999, Science.
[166] W. Jeffcoate,et al. Long‐term follow‐up of patients with hyperprolactinaemia , 1996, Clinical endocrinology.
[167] Marcel Karperien,et al. Printed in U.S.A. Copyright © 2000 by The Endocrine Society Expression of Vascular Endothelial Growth Factors and Their Receptors during Osteoblast Differentiation , 2022 .
[168] K. Alitalo,et al. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[169] A. Gazdar,et al. Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.
[170] B. Scheithauer,et al. Vascular endothelial growth factor (VEGF) expression in human pituitary adenomas and carcinomas , 1999, Endocrine pathology.
[171] R. Bergland,et al. Pituitary-brain vascular relations: a new paradigm. , 1979, Science.
[172] D. Hanahan,et al. Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.
[173] K. W. Kim,et al. Insulin-like growth factor II induced by hypoxia may contribute to angiogenesis of human hepatocellular carcinoma. , 1998, Cancer research.
[174] L. Formigli,et al. HPE cells: a clonal endothelial cell line established from human parathyroid tissue (human parathyroid cell line). , 1997, Endothelium : journal of endothelial cell research.
[175] J. Schechter. Ultrastructural changes in the capillary bed of human pituitary tumors. , 1972, The American journal of pathology.
[176] I. B. Borel Rinkes,et al. Continuous administration of angiostatin inhibits accelerated growth of colorectal liver metastases after partial hepatectomy. , 2000, Cancer research.
[177] K. Alitalo,et al. Vascular endothelial growth factor B, a novel growth factor for endothelial cells. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[178] E. Woltering,et al. Somatostatin analogues inhibit angiogenesis in the chick chorioallantoic membrane. , 1991, The Journal of surgical research.
[179] N. Weidner,et al. Correlation of intratumoral endothelial cell proliferation with microvessel density (tumor angiogenesis) and tumor cell proliferation in breast carcinoma. , 1994, The American journal of pathology.
[180] H. Namba,et al. Expression of parathyroid hormone related peptide in human pituitary tumours. , 1993, Journal of clinical pathology.
[181] J. Folkman,et al. Anti‐Angiogenesis: New Concept for Therapy of Solid Tumors , 1972, Annals of surgery.
[182] D. Gomez,et al. Ras oncogene mediated induction of a 92 kDa metalloproteinase; strong correlation with the malignant phenotype. , 1988, Biochemical and biophysical research communications.
[183] P. Maxwell. Oxygen homeostasis and cancer: insights from a rare disease. , 2002, Clinical medicine.
[184] M. Farquhar,et al. ELECTRON MICROSCOPIC STUDIES OF THE ANTERIOR PITUITARY GLAND , 1953, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[185] L. Jin,et al. Expression of D-type cyclins in normal and neoplastic rat pituitary. , 1998, Endocrinology.
[186] Donald R. Campbell,et al. Biphasic estrogen response on bovine adrenal medulla capillary endothelial cell adhesion, proliferation and tube formation , 1997, Molecular and Cellular Biochemistry.
[187] L. Mariani,et al. Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. , 1999, The American journal of pathology.
[188] A. Arnold,et al. Monoclonality of parathyroid tumors in chronic renal failure and in primary parathyroid hyperplasia. , 1995, The Journal of clinical investigation.
[189] J. Martial,et al. The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis. , 1993, Endocrinology.
[190] K. Kovacs,et al. Vascular alterations in adenomas of human pituitary glands. An electron microscopic study. , 1973, Angiologica.
[191] H. Sasano,et al. Vascularity in human adrenal cortex. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[192] I. Rooman,et al. Effect of vascular endothelial growth factor on growth and differentiation of pancreatic ductal epithelium. , 1997, Laboratory investigation; a journal of technical methods and pathology.
[193] T. Thompson,et al. Neuropeptides induce Mr 92,000 type IV collagenase (matrix metalloprotease-9) activity in human prostate cancer cell lines. , 1998, Cancer research.
[194] J. Franklyn,et al. Fibroblast growth factors 1 and 2 and fibroblast growth factor receptor 1 are elevated in thyroid hyperplasia. , 1998, The Journal of clinical endocrinology and metabolism.
[195] B. Woda,et al. Florid angiogenesis in mucosa surrounding an ileal carcinoid tumor expressing transforming growth factor-alpha. , 1997, The American journal of surgical pathology.
[196] Y. Okada,et al. Matrix metalloproteinase-9 (92 kDa gelatinase/type IV collagenase) from U937 monoblastoid cells: correlation with cellular invasion. , 1993, Journal of cell science.
[197] Thomas N. Sato,et al. Orchestration of angiogenesis and arteriovenous contribution by angiopoietins and vascular endothelial growth factor (VEGF) , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[198] K. Alitalo,et al. Tie receptors: new modulators of angiogenic and lymphangiogenic responses , 2001, Nature Reviews Molecular Cell Biology.
[199] E. van Marck,et al. Correlation of the fractions of proliferating tumor and endothelial cells in breast and colorectal adenocarcinoma is independent of tumor histiotype and microvessel density. , 1997, Microvascular research.
[200] Belghiti,et al. Expression of vascular endothelial growth factor in digestive neuroendocrine tumours , 1998, Histopathology.
[201] G. Martiny-Baron,et al. Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. , 1996, Cancer research.
[202] P. Chomczyński,et al. Human growth hormone stimulates proliferation of human retinal microvascular endothelial cells in vitro. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[203] M. Karkkainen,et al. Vascular endothelial growth factors are differentially regulated by steroid hormones and antiestrogens in breast cancer cells , 1999, Molecular and Cellular Endocrinology.
[204] D. Robie,et al. The expression of vascular endothelial growth factor and the type 1 vascular endothelial growth factor receptor correlate with the size of papillary thyroid carcinoma in children and young adults. , 2000, Thyroid : official journal of the American Thyroid Association.
[205] A. L. Goodman,et al. Thyroid angiogenesis: endotheliotropic chemoattractant activity from rat thyroid cells in culture. , 1987, Endocrinology.
[206] Q. Sang,et al. Complex role of matrix metalloproteinases in angiogenesis , 1998, Cell Research.
[207] M. Longaker,et al. Regulation of Vascular Endothelial Growth Factor Expression in Cultured Keratinocytes. , 1995, The Journal of Biological Chemistry.
[208] A. Harris,et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[209] M. Ivan,et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel–Lindau protein , 2000, Nature Cell Biology.
[210] A. Pozzi,et al. Basic fibroblast growth factor in human pheochromocytoma: A biochemical and immunohistochemical study , 1993, International journal of cancer.
[211] L. Jin,et al. Analysis of homogeneous populations of anterior pituitary folliculostellate cells by laser capture microdissection and reverse transcription-polymerase chain reaction. , 2001, Endocrinology.
[212] S. Melmed,et al. Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. , 1999, The Journal of clinical endocrinology and metabolism.
[213] M. Brandi. A novel endothelial cell growth factor circulates in familial multiple endocrine neoplasia type 1. , 1990, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.
[214] K. Alitalo,et al. Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. , 1998, Science.
[215] S. Iseki,et al. Immunohistochemical localization of vascular endothelial growth factor in the endocrine glands of the rat. , 1998, Archives of histology and cytology.
[216] S. Fukumoto,et al. Peroxisome Proliferator-Activated Receptor-γ Agonists Increase Vascular Endothelial Growth Factor Expression in Human Vascular Smooth Muscle Cells , 2000 .
[217] S. Kitano,et al. Anti-tumor angiogenesis therapy using soluble receptors: enhanced inhibition of tumor growth when soluble fibroblast growth factor receptor-1 is used with soluble vascular endothelial growth factor receptor , 2002, Cancer Gene Therapy.
[218] J. Folkman. Clinical Applications of Research on Angiogenesis , 1995 .
[219] S. Korem,et al. Similar and divergent patterns in the regulation of matrix metalloproteinase-1 (MMP-1) and tissue inhibitor of MMP-1 gene expression in benign and malignant human thyroid cells. , 1999, The Journal of clinical endocrinology and metabolism.
[220] J. Wass,et al. Antiangiogenic effects of somatostatin analogues , 2002, Clinical endocrinology.
[221] B. Scheithauer,et al. Vasculature in nontumorous hypophyses, pituitary adenomas, and carcinomas: A quantitative morphologic study , 1995, Endocrine pathology.
[222] Lars Holmgren,et al. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression , 1995, Nature Medicine.
[223] K. Alitalo,et al. Endothelial Tie growth factor receptor provides antigenic marker for assessment of breast cancer angiogenesis. , 1996, British Journal of Cancer.
[224] P. Carmeliet,et al. New perspectives in the function of pituitary folliculo-stellate cells , 1990, Molecular and Cellular Endocrinology.
[225] W Blumenfeld,et al. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. , 1993, The American journal of pathology.
[226] L. Bresler*,et al. Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma. , 2001, The Journal of clinical endocrinology and metabolism.
[227] S. Baylin,et al. Roles of trk family neurotrophin receptors in medullary thyroid carcinoma development and progression. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[228] A. Logan,et al. Basic fibroblast growth factor: an autocrine mitogen of rat thyroid follicular cells? , 1992, Endocrinology.
[229] M. Iruela-Arispe,et al. Antiangiogenic Domains Shared by Thrombospondins and Metallospondins, a New Family of Angiogenic Inhibitors , 1999, Annals of the New York Academy of Sciences.
[230] L. Liotta,et al. Distribution of the 72-kd type IV collagenase in nonneoplastic and neoplastic thyroid tissue. , 1992, Human pathology.
[231] L. Nelson,et al. Human follicle fluid vascular endothelial growth factor concentrations are correlated with luteinization in spontaneously developing follicles. , 1998, Human reproduction.
[232] M. Greaves,et al. Leukocyte antigen CD34 is expressed by a subset of cultured endothelial cells and on endothelial abluminal microprocesses in the tumor stroma. , 1990, Laboratory investigation; a journal of technical methods and pathology.
[233] Steven A. Stacker,et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics , 2001, Nature Medicine.
[234] H. Esumi,et al. Regulation of vascular endothelial growth factor expression by insulin‐like growth factor‐I in endometrial adenocarcinoma cells , 2000, International journal of cancer.
[235] W. Risau,et al. Mechanisms of angiogenesis , 1997, Nature.
[236] G. Semenza,et al. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation , 1992, Molecular and cellular biology.
[237] K. Kairemo,et al. Inhibition of malignant angiogenesis. , 1997, Cancer treatment reviews.
[238] N. Palanisamy,et al. Novel chromosomal abnormalities identified by comparative genomic hybridization in parathyroid adenomas. , 1998, The Journal of clinical endocrinology and metabolism.
[239] R. Tuan,et al. Expression of Angiogenic Growth Factors in Paragangliomas , 2000, The Laryngoscope.
[240] M. Shibuya. Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. , 2001, Cell structure and function.
[241] G. Bechtner,et al. Release of an endothelial cell growth factor from cultured porcine thyroid follicles. , 1989, Molecular endocrinology.
[242] K. Suzuki,et al. Matrix metalloproteinases as insulin-like growth factor binding protein-degrading proteinases. , 1995, Progress in growth factor research.
[243] S. Kumar,et al. A monoclonal antibody detects heterogeneity in vascular endothelium of tumours and normal tissues , 1993, International journal of cancer.
[244] H. Kihara,et al. Pituitary folliculo-stellate cells immunostained with S-100 protein antiserum in postnatal, castrated and thyroidectomized rats , 2004, Cell and Tissue Research.
[245] R. Coffey,et al. Human carcinoid cell production of paracrine growth factors that can stimulate fibroblast and endothelial cell growth. , 1991, Cancer research.
[246] Seppo Ylä-Herttuala,et al. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3 , 2001, Nature Medicine.
[247] G. Semenza. HIF-1 and mechanisms of hypoxia sensing. , 2001, Current opinion in cell biology.
[248] P. Comoglio,et al. Hepatocyte growth factor (HGF) stimulates tumour invasiveness in papillary carcinoma of the thyroid , 1999, The Journal of pathology.
[249] J. Tímár,et al. Multiple Roles for Platelet GPIIb/IIIa and αvβ3 Integrins in Tumor Growth, Angiogenesis, and Metastasis , 2002 .
[250] D. Birnbaum,et al. VEGFc and VEGFR3 expression in human thyroid pathologies , 2000, International journal of cancer.
[251] F. Trimarchi,et al. Expression of the hepatocyte growth factor and c-met in normal thyroid, non-neoplastic, and neoplastic nodules. , 1998, Thyroid : official journal of the American Thyroid Association.
[252] C. Powers,et al. Fibroblast growth factors, their receptors and signaling. , 2000, Endocrine-related cancer.
[253] R. Hammer,et al. The hypoxia-responsive transcription factor EPAS1 is essential for catecholamine homeostasis and protection against heart failure during embryonic development. , 1998, Genes & development.
[254] Karl H. Plate,et al. From angiogenesis to lymphangiogenesis , 2001, Nature Medicine.
[255] M. Brandi,et al. Increased basic fibroblast growth factor in plasma from multiple endocrine neoplasia type 1: relation to pituitary tumor. , 1993, The Journal of clinical endocrinology and metabolism.
[256] Y. Shiotani. An electron microscopic study on stellate cells in the rabbit adenohypophysis under various endocrine conditions , 1980, Cell and Tissue Research.
[257] A. Harris,et al. Quantitation and prognostic value of breast cancer angiogenesis: Comparison of microvessel density, Chalkley count, and computer image analysis , 1995, The Journal of pathology.
[258] M. Rechler,et al. Proteolysis of Insulin-Like Growth Factor Binding Protein-3 in Serum from Pregnant, Non-Pregnant and Fetal Rats by Matrix Metalloproteinases and Serine Proteases , 1999, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
[259] K. Alitalo,et al. A novel vascular endothelial growth factor, VEGF‐C, is a ligand for the Flt4 (VEGFR‐3) and KDR (VEGFR‐2) receptor tyrosine kinases. , 1996, The EMBO journal.
[260] E. Woltering,et al. Postreceptor signal transduction mechanisms involved in octreotide-induced inhibition of angiogenesis. , 1994, Surgery.
[261] W. Scherbaum,et al. mRNA levels of membrane-type 1 matrix metalloproteinase (MT1-MMP), MMP-2, and MMP-9 and of their inhibitors TIMP-2 and TIMP-3 in normal thyrocytes and thyroid carcinoma cell lines. , 1998, Thyroid : official journal of the American Thyroid Association.
[262] J. Silverlight,et al. BASIC FIBROBLAST GROWTH FACTOR IN HUMAN PITUITARY TUMOURS , 1990, Clinical endocrinology.
[263] D. Hanahan,et al. Vascular endothelial growth factor and its receptors, flt-1 and flk-1, are expressed in normal pancreatic islets and throughout islet cell tumorigenesis. , 1995, Molecular endocrinology.
[264] L. Liotta,et al. Extracellular matrix 6: Role of matrix metalloproteinases in tumor invasion and metastasis , 1993, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[265] S. Melmed,et al. Human pituitary tumor-transforming gene induces angiogenesis. , 2001, The Journal of clinical endocrinology and metabolism.
[266] G. Stancel,et al. Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor. , 2000, Cancer research.
[267] X. Bertagna,et al. Rearrangements at the 11p15 locus and overexpression of insulin-like growth factor-II gene in sporadic adrenocortical tumors. , 1994, The Journal of clinical endocrinology and metabolism.
[268] S. Fox,et al. Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. , 1996, European journal of cancer.
[269] Janice A. Nagy,et al. The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor , 2001, Nature Medicine.
[270] Leonard,et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. , 1997, Cancer research.
[271] M. Shibuya,et al. Expression of vascular endothelial growth factor (VEGF) in human thyroid neoplasms. , 1999, Human pathology.
[272] A. Ferrando,et al. Structure and expression in breast tumors of human TIMP-3, a new member of the metalloproteinase inhibitor family. , 1994, Cancer research.
[273] D. Mukhopadhyay,et al. High cell density induces vascular endothelial growth factor expression via protein tyrosine phosphorylation. , 1998, Gene expression.
[274] Kenneth J. Hillan,et al. Vascular endothelial growth factor is essential for corpus luteum angiogenesis , 1998, Nature Medicine.
[275] K. Kołomecki,et al. Vascular endothelial growth factor and basic fibroblast growth factor evaluation in blood serum of patients with hormonally active and inactive adrenal gland tumours. , 2000, Cytobios.
[276] F. Peillon,et al. Specific alterations of the basement membrane and stroma antigens in Human pituitary tumours in comparison with the normal anterior pituitary. An immunocytochemical study , 2005, Virchows Archiv.
[277] C. Lotfi,et al. Control of the adrenocortical cell cycle: interaction between FGF2 and ACTH. , 1999, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.
[278] N. Ferrara,et al. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. , 1989, Biochemical and biophysical research communications.
[279] H. Wieland,et al. Induction of vascular endothelial growth factor by platelet-activating factor and platelet-derived growth factor is downregulated by corticosteroids. , 1997, American journal of respiratory cell and molecular biology.
[280] N. Simionescu,et al. Structural aspects of the permeability of the microvascular endothelium. , 1979, Acta physiologica Scandinavica. Supplementum.
[281] T. Obara,et al. Insulin-like growth factor I receptors and insulin-like growth factor-binding proteins in human parathyroid tumors , 1994, World Journal of Surgery.
[282] William Arbuthnot Sir Lane,et al. Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.
[283] B. Scheithauer,et al. Microvessel density in pituitary adenomas and carcinomas , 2001, Virchows Archiv.
[284] H. Sugimura,et al. Antitumor Effect of a Neutralizing Antibody to Vascular Endothelial Growth Factor on Liver Metastasis of Endocrine Neoplasm , 1998, Japanese journal of cancer research : Gann.
[285] K. Alitalo,et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[286] J. Folkman,et al. TUMOR DORMANCY IN VIVO BY PREVENTION OF NEOVASCULARIZATION , 1972, The Journal of experimental medicine.
[287] D. Benezra. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase-3. , 1997, Investigative ophthalmology & visual science.
[288] G. Popa. A Portal Circulation from the Pituitary to the Hypothalamic Region. , 1930, Journal of anatomy.
[289] V. Dixit,et al. Aberrant production of interleukin-8 and thrombospondin-1 by psoriatic keratinocytes mediates angiogenesis. , 1994, The American journal of pathology.
[290] G. Fontanini,et al. Microvessel count: an indicator of poor outcome in medullary thyroid carcinoma but not in other types of thyroid carcinoma. , 1996, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[291] D. Robertson,et al. Matrix metalloproteinases 2 and 9 in canine rheumatoid arthritis , 1998, Veterinary Record.
[292] R Bicknell,et al. Relationship of endothelial cell proliferation to tumor vascularity in human breast cancer. , 1993, Cancer research.
[293] R. Weiner,et al. Inhibition of estrogen-induced anterior pituitary enlargement and arteriogenesis by bromocriptine in Fischer 344 rats. , 1987, Endocrinology.
[294] J. Bertherat,et al. Pathogenesis of adrenocortical incidentalomas and genetic syndromes associated with adrenocortical neoplasms. , 2000, Endocrinology and metabolism clinics of North America.
[295] T. Porter,et al. Stimulation of lactotrope differentiation in vitro by fibroblast growth factor. , 1994, Endocrinology.
[296] M. Shibuya,et al. Increase of vascular endothelial growth factor mRNA expression by 1,25‐dihydroxyvitamin D3 in human osteoblast‐like cells , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[297] J. Chudek,et al. Genetic abnormalities in parathyroid nodules of uremic patients. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[298] B. Scheithauer,et al. Localization of vascular endothelial growth factor in nontumorous human pituitaries , 1999, Endocrine pathology.
[299] H. Sugihara,et al. Fibroblast growth factor-2 free from extracellular matrix is increased in papillary thyroid carcinomas and Graves' thyroids. , 1998, Thyroid : official journal of the American Thyroid Association.
[300] K. W. Kim,et al. Identification of angiogenic properties of insulin-like growth factor II in in vitro angiogenesis models , 2000, British Journal of Cancer.
[301] H. Yamaguchi,et al. S100 protein in folliculostellate cells of the rat pituitary anterior lobe , 1980, Brain Research.
[302] S. Dobbs,et al. Angiogenesis is associated with vascular endothelial growth factor expression in cervical intraepithelial neoplasia. , 1997, British Journal of Cancer.
[303] L. Ding,et al. Controlling tumor angiogenesis and metastasis of C26 murine colon adenocarcinoma by a new matrix metalloproteinase inhibitor, KB-R7785, in two tumor models. , 1999, Cancer research.
[304] N. Usuda,et al. Therapeutic efficacy of the angiogenesis inhibitor O-(chloroacetyl-carbamoyl) fumagillol (TNP-470; AGM-1470) for human anaplastic thyroid carcinoma in nude mice. , 1997, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.
[305] J. Gogusev,et al. De novo expression of transforming growth factor-alpha in parathyroid gland tissue of patients with primary or secondary uraemic hyperparathyroidism. , 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[306] S. Asa,et al. Heterogenous in vivo and in vitro expression of basic fibroblast growth factor by human pituitary adenomas. , 1995, The Journal of clinical endocrinology and metabolism.
[307] C. Readhead,et al. Pituitary-directed leukemia inhibitory factor transgene forms Rathke's cleft cysts and impairs adult pituitary function. A model for human pituitary Rathke's cysts. , 1997, The Journal of clinical investigation.
[308] M. Feinmesser,et al. Angiogenesis in follicular tumors of the thyroid , 1996, Journal of surgical oncology.
[309] H. Namba,et al. Inhibition of angiogenesis and tumorigenesis, and induction of dormancy by p53 in a p53-null thyroid carcinoma cell line in vivo. , 2000, Anticancer research.
[310] M. Beato,et al. Inducible regulatory elements in the human cyclin D1 promoter. , 1994, Oncogene.
[311] N. Hashimoto,et al. Immunohistochemical study for basic fibroblast growth factor and fibroblast growth factor receptor I in pituitary adenomas , 1994, Neuroscience Letters.
[312] H. Höfler,et al. Immunohistochemistry of folliculo-stellate cells in normal human adenohypophyses and in pituitary adenomas , 2004, Acta Neuropathologica.
[313] G. Stancel,et al. Progestin regulation of vascular endothelial growth factor in human breast cancer cells. , 1998, Cancer research.
[314] M. Neeman,et al. Stabilization of vascular endothelial growth factor mRNA by hypoxia and hypoglycemia and coregulation with other ischemia-induced genes , 1995, Molecular and cellular biology.
[315] A. Arnold,et al. Coding sequence of the overexpressed transcript of the putative oncogene PRAD1/cyclin D1 in two primary human tumors. , 1993, Oncogene.
[316] H. Jabbour,et al. Pattern and localisation of expression of vascular endothelial growth factor and its receptor flt-1 in the ovine pituitary gland: expression is independent of hypothalamic control , 1997, Molecular and Cellular Endocrinology.
[317] T. Obara,et al. Vascular endothelial growth factor-C gene expression in papillary and follicular thyroid carcinomas. , 1999, Surgery.
[318] F. Trimarchi,et al. Loss of heterozygosity of the long arm of chromosome 7 in follicular and anaplastic thyroid cancer, but not in papillary thyroid cancer. , 1999, The Journal of clinical endocrinology and metabolism.
[319] S. Melmed,et al. Isolation and characterization of a pituitary tumor-transforming gene (PTTG). , 1997, Molecular endocrinology.
[320] D. Millhorn,et al. Hypoxia Induces Phosphorylation of the Cyclic AMP Response Element-binding Protein by a Novel Signaling Mechanism* , 1998, The Journal of Biological Chemistry.
[321] B. Scheithauer,et al. Immunolocalization of vascular endothelial growth factor in the GH3 cell line , 2000, Cell and Tissue Research.
[322] A. Giatromanolaki,et al. Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[323] K. Kameyama. Expression of MMP-1 in the capsule of thyroid cancer--relationship with invasiveness. , 1996, Pathology, research and practice.
[324] J. Folkman. What is the evidence that tumors are angiogenesis dependent? , 1990, Journal of the National Cancer Institute.
[325] D. Ribatti,et al. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. , 1999, Blood.
[326] K. Horgan,et al. Effect of Growth Factors on Growth of Bovine Parathyroid Cells in Serum-Free Medium , 1996, World Journal of Surgery.
[327] M. Noguchi,et al. Enhanced production and activation of progelatinase A mediated by membrane-type 1 matrix metalloproteinase in human papillary thyroid carcinomas. , 1999, Cancer research.
[328] G. Mashour,et al. Aberrant cutaneous expression of the angiogenic factor midkine is associated with neurofibromatosis type-1. , 1999, The Journal of investigative dermatology.
[329] W. Kaelin,et al. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[330] S. Fox,et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenes , 1997, Cancer research.
[331] C. Martínez-A,et al. Insulin-like growth factor I-triggered cell migration and invasion are mediated by matrix metalloproteinase-9. , 1999, Endocrinology.
[332] R. Luna,et al. Cell cycle regulated expression and phosphorylation of hpttg proto-oncogene product , 2000, Oncogene.
[333] J. Folkman. Editorial: Is Tissue Mass Regulated by Vascular Endothelial Cells? Prostate as the First Evidence. , 1998, Endocrinology.
[334] P. Kelly,et al. The prolactin gene is expressed in the hypothalamic-neurohypophyseal system and the protein is processed into a 14-kDa fragment with activity like 16-kDa prolactin. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[335] C. Larsson,et al. Gelatinase A and Membrane-type 1 Matrix Metalloproteinase mRNA: Expressed in Adrenocortical Cancers but Not in Adenomas , 1999, World Journal of Surgery.
[336] M. Tachibana,et al. Tumor vascularity predicts recurrence in differentiated thyroid carcinoma. , 1998, American journal of surgery.
[337] K. Alitalo,et al. Vascular growth factors and lymphangiogenesis. , 2002, Physiological reviews.
[338] S M Schwartz,et al. Angiogenesis in human coronary atherosclerotic plaques. , 1994, The American journal of pathology.
[339] M. Capdevielle,et al. Angiogenic activity of anterior pituitary tissue and growth hormone on the chick embryo chorio-allantoic membrane: a novel action of GH. , 1995, Life sciences.
[340] Lois E. H. Smith,et al. Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor , 1999, Nature Medicine.
[341] E. Keshet,et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis , 1992, Nature.
[342] K. Yamazaki,et al. Stimulation by thyroid-stimulating hormone and Grave's immunoglobulin G of vascular endothelial growth factor mRNA expression in human thyroid follicles in vitro and flt mRNA expression in the rat thyroid in vivo. , 1995, The Journal of clinical investigation.
[343] J. Rosai,et al. Localization of factor VIII-related antigen in vascular endothelial cells using an immunoperoxidase method. , 1980, The American journal of surgical pathology.
[344] A. Giatromanolaki,et al. Assessment of vascular maturation in non-small cell lung cancer using a novel basement membrane component, LH39: correlation with p53 and angiogenic factor expression. , 1999, Cancer research.
[345] W. Carter,et al. Stimulation of angiogenesis by canine parathyroid tissue. , 1996, Surgery.
[346] R. Weiner,et al. A specific, high affinity, saturable binding site for the 16-kilodalton fragment of prolactin on capillary endothelial cells. , 1992, Endocrinology.
[347] A. Irrthum,et al. A gene for inherited cutaneous venous anomalies ("glomangiomas") localizes to chromosome 1p21-22. , 1999, American journal of human genetics.
[348] A. Kossakowska,et al. Comparative analysis of the expression patterns of metalloproteinases and their inhibitors in breast neoplasia, sporadic colorectal neoplasia, pulmonary carcinomas and malignant non-Hodgkin's lymphomas in humans. , 1996, British Journal of Cancer.
[349] A. Miettinen,et al. Ulex europaeus I lectin as a marker for vascular endothelium in human tissues. , 1982, Laboratory investigation; a journal of technical methods and pathology.
[350] T. L. Moser,et al. Angiostatin binds ATP synthase on the surface of human endothelial cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[351] A. Bergh,et al. Testosterone stimulates angiogenesis and vascular regrowth in the ventral prostate in castrated adult rats. , 1998, Endocrinology.
[352] K. Dameron,et al. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. , 1994, Science.
[353] R. Khokha,et al. Insulin-like Growth Factor II Signaling in Neoplastic Proliferation Is Blocked by Transgenic Expression of the Metalloproteinase Inhibitor Timp-1 , 1999, The Journal of cell biology.
[354] R. Deitch. The start of a long debate on the Warnock report. , 1984, Lancet.
[355] D. Ribatti,et al. Anti-angiogenic activity of the purine analog 6-thioguanine , 2002, Leukemia.
[356] J. Folkman,et al. Quantitation of angiogenesis and antiangiogenesis in the chick embryo chorioallantoic membrane. , 1994, Microvascular research.
[357] M. Stack,et al. The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin , 1997 .
[358] N. Ferrara,et al. Corticotropin regulates vascular endothelial growth factor expression in human fetal adrenal cortical cells. , 1998, The Journal of clinical endocrinology and metabolism.
[359] Janet Rossant,et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice , 1995, Nature.
[360] J. Schlessinger. Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.
[361] P. Cohen,et al. Leukotriene D4 induces MMP-1, which functions as an IGFBP protease in human airway smooth muscle cells. , 1996, The American journal of physiology.
[362] F. Sarkar,et al. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. , 1995, The Journal of clinical investigation.
[363] L. Liotta,et al. Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation , 1991, Cell.
[364] A. Harvey,et al. Intermittent administration of parathyroid hormone (1‐34) stimulates matrix metalloproteinase‐9 (MMP‐9) expression in rat long bone , 1998, Journal of cellular biochemistry.
[365] D. Donner,et al. Induction of Vascular Endothelial Growth Factor by Insulin-like Growth Factor 1 in Colorectal Carcinoma* , 1996, The Journal of Biological Chemistry.
[366] T. Yamamoto,et al. Therapeutic usefulness of wild-type p53 gene introduction in a p53-null anaplastic thyroid carcinoma cell line. , 1998, The Journal of clinical endocrinology and metabolism.
[367] A. Ullrich,et al. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. , 1996, Cancer research.
[368] B. J. Harrison,et al. Fibroblast Growth Factors and Their Receptors in Parathyroid Disease , 1998, World Journal of Surgery.
[369] A. Arnold,et al. Loss of chromosome arm 9p DNA and analysis of the p16 and p15 cyclin-dependent kinase inhibitor genes in human parathyroid adenomas. , 1996, The Journal of clinical endocrinology and metabolism.
[370] M. Gerritsen,et al. Peroxisome Proliferator-activated Receptor γ Ligands Are Potent Inhibitors of Angiogenesis in Vitro and in Vivo * , 1999, The Journal of Biological Chemistry.
[371] K. Usadel,et al. T lymphocytes, CD68-positive cells and vascularisation in thyroid carcinomas , 2005, Journal of Cancer Research and Clinical Oncology.
[372] A. Harris,et al. Angiogenesis in pituitary adenomas - relationship to endocrine function, treatment and outcome. , 2000, Journal of Endocrinology.
[373] B. Olffson. Vascular endothelial grouth facter B, a novel growth facter for endothelial cells , 1996 .
[374] J. Widdicombe,et al. Transport epithelial characteristics of cultured bovine pituitary follicular cells. , 1987, The American journal of physiology.
[375] F Pozza,et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. , 1992, Journal of the National Cancer Institute.
[376] J. Fiddes,et al. Basic fibroblast growth factor: production and growth stimulation in cultured adrenal cortex cells. , 1987, Endocrinology.
[377] U. Moll,et al. Mr 92,000 Type IV Collagenase Is Increased in Plasma of Patients with Colon Cancer and Breast Cancer , 1993 .
[378] W. Cavenee,et al. Expression of vascular endothelial growth factor in human brain tumors , 1998, Acta Neuropathologica.
[379] N. Harris,et al. PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[380] S. Melmed,et al. Human and murine pituitary expression of leukemia inhibitory factor. Novel intrapituitary regulation of adrenocorticotropin hormone synthesis and secretion. , 1995, The Journal of clinical investigation.
[381] N. Ferrara,et al. The 16K fragment of prolactin specifically inhibits basal or fibroblast growth factor stimulated growth of capillary endothelial cells. , 1991, Endocrinology.
[382] T. Terada,et al. An immunohistochemical study of tumour vessels in metastatic liver cancers and the surrounding liver tissue , 1996, Histopathology.
[383] P. Esbrit,et al. C-terminal parathyroid hormone-related protein increases vascular endothelial growth factor in human osteoblastic cells. , 2000, Journal of the American Society of Nephrology : JASN.
[384] N. Ferrara,et al. Vascular endothelial growth factor and the regulation of angiogenesis. , 2000, Recent progress in hormone research.
[385] Y. Chung,et al. Tumor angiogenesis as a predictor of recurrence in gastric carcinoma. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[386] Bao Q. Pham,et al. Curcuminoids Inhibit the Angiogenic Response Stimulated by Fibroblast Growth Factor-2, Including Expression of Matrix Metalloproteinase Gelatinase B* , 2000, The Journal of Biological Chemistry.
[387] Lois E. H. Smith,et al. Essential role of growth hormone in ischemia-induced retinal neovascularization. , 1997, Science.
[388] E. Laws,et al. The primary angiographic findings in pituitary adenomas. , 1974, Radiology.
[389] Q. Duh,et al. Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid. , 1997, The Journal of clinical endocrinology and metabolism.
[390] W T Yuh,et al. Sequential MR enhancement pattern in normal pituitary gland and in pituitary adenoma. , 1994, AJNR. American journal of neuroradiology.
[391] S. Tsuchiya,et al. Expression of basic fibroblast growth factor in hyperplastic parathyroid glands from patients with multiple endocrine neoplasia type I , 1994, World Journal of Surgery.
[392] P. Brodt,et al. Regulation of the Mr 72,000 type IV collagenase by the type I insulin-like growth factor receptor. , 1998, Cancer research.
[393] P. Sharp. The role of growth factors in the development of diabetic retinopathy. , 1995, Metabolism: clinical and experimental.
[394] S. Fox,et al. Relationship of vascular maturation in breast cancer blood vessels to vascular density and metastasis, assessed by expression of a novel basement membrane component, LH39 , 2000, British Journal of Cancer.
[395] M. Stack,et al. Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin. , 1996, Cancer research.
[396] J. Rossant,et al. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium , 1995, Nature.
[397] T. Nakamura,et al. Hepatocyte growth factor increases expression of vascular endothelial growth factor and plasminogen activator inhibitor-1 in human keratinocytes and the vascular endothelial growth factor receptor flk-1 in human endothelial cells. , 1999, Laboratory investigation; a journal of technical methods and pathology.